Urinary tract infection

Zemdri Approved to Treat Complicated Urinary Tract Infections

By June 26, 2018

Zemdri carries a Boxed Warning describing reports of nephrotoxicity, ototoxicity, and neuromuscular blockade, as well as fetal harm if administered during pregnancy.

FDA Panel Votes on Plazomicin for Complicated UTI, Bloodstream Infections

By May 03, 2018

The Committee voted unanimously (15-0) that substantial evidence on the safety and efficacy of plazomicin was presented for the treatment of cUTI but voted against its use (4-11) for the treatment of bloodstream infections in patients with limited or no treatment options.

Combination Antibiotics Compared in the Treatment of Complicated UTI

By February 28, 2018

The results showed that meropenem/vaborbactam was non-inferior to piperacillin/tazobactam with an overall success rate of 98.4% vs 94.0%.

Nitrofurantoin, TMP-SMX Often Prescribed in Early Pregnancy for UTI

By January 17, 2018

A 2011 committee opinion from the American College of Obstetricians and Gynecologists (ACOG) recommended that sulfonamides and nitrofurantoin may be prescribed in the first trimester of pregnancy only when other antimicrobial therapies are deemed clinically inappropriate.

FDA Clears UriVarx Test Strips for UTI Detection

By January 11, 2018

The supplements are intended to reduce urinary urgency, accidents, and day/night frequency in patients with overactive bladder and urinary infections.

NSAID Compared to Antibiotic for Symptomatic Treatment of UTI

By November 09, 2017

The primary endpoint of symptom resolution at day 3 was met by 54% (72/133) in the diclofenac group vs. 80% (96/120) in the norfloxacin group (risk difference 27%, 95% CI 15% to 38%, P=0.98 for non-inferiority, P<0.001 for superiority).

FDA Approves Unique Antibiotic Combo Drug Vabomere

By August 30, 2017

Vabomere is a combination antibiotic that includes meropenem, a penem antibacterial, and vaborbactam, a non-suicidal beta-lactamase inhibitor.

Carbavance Gets Priority Review for Complicated UTI

By February 21, 2017

The study met the pre-specified primary endpoints and showed that treatment with Carbavance is associated with an overall success rate of 98.4%.

UTI Treatment Leads to Fatal Drug Interaction in a Schizophrenia Patient

By November 23, 2016

This case is the first to describe a fatal outcome with such an interaction.